Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer

Source link :

SAN DIEGO — A preoperative combination of chemotherapy and immunotherapy (IO) appeared safe and effective for borderline resectable pancreatic cancer in a small pilot study, a researcher reported here. In the phase I/II trial, neoadjuvant treatment with modified FOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) plus nivolumab (Opdivo) was associated with favorable rates of R0 […]

Author : News Health

Publish date : 2024-04-10 21:42:30

Copyright for syndicated content belongs to the linked Source.